Andriy Moshyk
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Health Systems, Economic Evaluations, Quality of Life, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways
Most-Cited Works
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Depression and mortality in the visually‐impaired, community‐dwelling, elderly population of Quebec(2008)52 cited
- → First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data(2024)47 cited
- → Integrating feedback from a clinical data warehouse into practice organisation(2005)45 cited
- → Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067(2021)34 cited
- → Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial(2021)31 cited
- → Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada(2015)23 cited
- → A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆(2021)21 cited
- → Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma(2021)20 cited
- → Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis(2021)18 cited